GLP1R and fatty liver disease: Taken together, our data suggest that pharmacological inhibition of miR-22 function could represent a viable therapeutic strategy for obesity and liver steatosis, with a mechanism that would be complementary to treatment with GLP1 receptor agonist drugs [22,28,29], enabling the development of novel combination therapies for more effective treatment of obesity.